Clinicopathologic and prognosis of 30 patients with FH-deficient renal cell carcinoma: a single-center retrospective study

Clinicopathologic and prognosis of 30 patients with FH-deficient renal cell carcinoma: a single-center retrospective study

Abstract Background FH-Deficient Renal Cell Carcinoma (FH-RCC) is a rare, aggressive cancer with poor prognosis and treatment challenges. Immunohistochemical (IHC), including PD-1, PD-L1, PD-L2, and CTLA-4, play a key role in survival outcomes and therapeutic decisions, highlighting the need to eval...

Full description

Saved in:

Bibliographic Details
Main Authors:	Junjie Bai, Jianjia Huang, Yushi Ye, Jun Lin, Yahui Wen, Zicheng Cai, Peihuang Chen, Tong Shangguan, Gaoyu Zou, Qianyi Qiu, Ru Chen, Rong Liu, Weizhong Cai, Shaoxing Zhu, Jianhui Chen, Xiaoyan Li
Format:	Article
Language:	English
Published:	BMC 2025-07-01
Series:	BMC Cancer
Subjects:	FH-Deficient renal cell carcinoma Immunohistochemical Programmed death ligand-1 (PD-L1) Programmed death ligand-2 (PD-L2)
Online Access:	https://doi.org/10.1186/s12885-025-14562-6
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-world data on immune checkpoint inhibitors in advanced sarcomas across multiple European institutions
by: Stefania Kokkali, et al.
Published: (2025-06-01)

Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck
by: Yu. V. Kostalanova, et al.
Published: (2020-11-01)

Understanding and overcoming resistance to immunotherapy in genitourinary cancers
by: Sean T Evans, et al.
Published: (2024-12-01)

Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors
by: Seher Şener, et al.
Published: (2021-10-01)

Influence of programmed death ligand 1 (PD-L1) knockout on gut microbiota in experimental autoimmune uveitis
by: Junxiang Gu, et al.
Published: (2025-05-01)

PD-L1 deficiency exacerbates colitis severity by remodeling gut microbiota in inflammatory bowel disease
by: Yixian Ma, et al.
Published: (2025-06-01)

Predicting PD-L1 status in NSCLC patients using deep learning radiomics based on CT images
by: Jiameng Lu, et al.
Published: (2025-04-01)

PD-L1 on Circulating Tumor Cells Indicates Poor Prognosis in Breast Cancer
by: Xue-fei Wang, et al.
Published: (2022-11-01)

Development and Validation of a Biolayer Interferometry Method for Determination of Human Anti-PD-1 Monoclonal Antibody Concentration in Cynomolgus Serum
by: K. V. Ulyanova, et al.
Published: (2020-12-01)

The features of PD-L1 expression in tumor stromal cells, peritumoral microvessels and isolated clusters of tumor cells in breast cancer tissue and their correlation with clinical and morphological characteristics of breast cancer
by: E. Yu. Zubareva, et al.
Published: (2023-11-01)

Immune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study
by: Anastasia Rays, et al.
Published: (2025-03-01)

Accessing utility of immunohistochemistry, PD-L1 correlation with stage of cancer and EGFR mutation with disease survival in primary lung carcinoma
by: Kartavya Kumar Verma, et al.
Published: (2025-06-01)

Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring
by: Chunyan Liu, et al.
Published: (2023-04-01)

A novel deep learning framework for automatic scoring of PD-L1 expression in non-small cell lung cancer
by: Saidul Kabir, et al.
Published: (2025-03-01)

Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors combined with chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis
by: Jiaojiao Yu, et al.
Published: (2025-05-01)

Detection of PD-L1 expression levels in malignant pleural mesothelioma with a targeted MRI nanoprobe in vivo
by: Zhenghua Zhang, et al.
Published: (2024-12-01)

Isolated tumor cell clusters (ITC) in lymph nodes and PD-L1 expression on tumor-associated immune cells are prognostic factors for microsatellite instable-high gastric cancers
by: Menghan Cui, et al.
Published: (2025-09-01)

Evaluation of the diagnostic concordance of FDA-approved PD-L1 assays in clear cell renal cell carcinoma
by: Yoko Koh, et al.
Published: (2025-07-01)

Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
by: Hanan R. Nada, et al.
Published: (2025-01-01)

Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis
by: Tzu-Rong Peng, et al.
Published: (2023-11-01)

Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review
by: T. N. Sotnikova, et al.
Published: (2023-07-01)

Case Report: Long-term response control in a patient with metastatic gastric squamous cell carcinoma treated with nivolumab and chemoradiotherapy
by: Yu-ying Lei, et al.
Published: (2025-08-01)

Development of caninized anti-CTLA-4 antibody as salvage combination therapy for anti-PD-L1 refractory tumors in dogs
by: Naoya Maekawa, et al.
Published: (2025-05-01)

Programmed death‐ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2‐negative status
by: Lei Wang, et al.
Published: (2018-06-01)

A Multispecific Checkpoint Inhibitor Nanofitin with a Fast Tumor Accumulation Property and Anti-Tumor Activity in Immune Competent Mice
by: Perrine Jacquot, et al.
Published: (2025-03-01)

The prognostic implications of podoplanin in cancer‐associated fibroblasts and PD‐L1 expression in high‐grade neuroendocrine carcinoma of the lung
by: Tatsuya Miyamoto, et al.
Published: (2024-12-01)

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01)

mRNA and protein expression of programmed cell death-ligand-1 on canine mammary gland tumour in dogs of Chiang Mai, Thailand
by: Wanwisa Srisawat, et al.
Published: (2025-12-01)

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis
by: Shiya Ji, et al.
Published: (2025-02-01)

CD4 T cells correlate with better prognosis in medulloblastoma
by: Jin Zhang, et al.
Published: (2025-06-01)

Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression
by: Wei-Wen Sung, et al.
Published: (2022-01-01)

Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA
by: Mushi Chen, et al.
Published: (2019-12-01)

Recent advances in the mechanisms of PD-L1 expression in gastric cancer: a review
by: Peifeng Chen, et al.
Published: (2025-03-01)

Anti‐PD‐1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases
by: Pooja Dhupkar, et al.
Published: (2018-06-01)

Transcriptional, growth factors, components of the AKT/mTOR signaling pathway, receptors and ligands of programmed cell death expression in melanoma
by: K. V. Nikulnikov, et al.
Published: (2024-04-01)

Targeting Neuronal Nitric Oxide Synthase (nNOS) as a Novel Approach to Enhancing the Anti-Melanoma Activity of Immune Checkpoint Inhibitors
by: Anika Patel, et al.
Published: (2025-05-01)

Programmed Cell Death Ligand 1 (PD-L1) and major Histocompatibility Complex Class I (MHC Class I) Expression Patterns and Their Pathologic Associations in triple-Negative Breast Cancer
by: Kaewkedsri P, et al.
Published: (2025-02-01)

Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies
by: Richard S. Finn, et al.
Published: (2025-06-01)

Discovery and functional characterization of canine PD-L1-targeted antibodies for evaluating antitumor efficacy in a canine osteosarcoma xenograft model
by: Min-young Song, et al.
Published: (2025-03-01)

Effects of chemoradiotherapy on surface PD-L1 expression in esophageal cancer and its implications for immunotherapy
by: Lovis Hampe, et al.
Published: (2024-12-01)